Core Viewpoint - The core competitive advantage of the company lies in its digital system, which enables a full-loop data management from production to consumption, providing precise support for business growth [1] Digital System Overview - The company utilizes "five-in-one" technology to track the entire process of product production, distribution, terminal sales, and promotional verification [1] - Real-time access to key information such as channel inventory and sales data is achieved through this system [1] Operational Efficiency - The digital operating system is built around the supply chain, production bases, channel partners, and end consumers, creating a comprehensive, multi-layered, and integrated operational framework [1] - This system empowers critical operational aspects, driving sales growth, enhancing decision-making accuracy, and achieving comprehensive cost reduction and efficiency improvement [1]

Group 1 - The European Union has announced a six-month suspension of retaliatory tariffs against the United States [1] - Eurozone manufacturing PMI unexpectedly rose to 49.4 in January [2] - The U.S. Department of Defense has prioritized homeland defense in its National Defense Strategy [4] Group 2 - The two-year U.S. Treasury yield decreased by 0.13 basis points to 3.594% [4] - The five-year U.S. Treasury yield fell by 1.39 basis points to 3.825% [4] - The ten-year U.S. Treasury yield dropped by 1.57 basis points to 4.225% [4] Group 3 - The Nasdaq index closed at 23,501.24, up by 0.28% [5] - The Dow Jones Industrial Average closed at 49,098.71, down by 0.58% [5] - The S&P 500 index closed at 6,915.61, up by 0.03% [5] Group 4 - The Baltic Dry Index closed at 1,762.00, up by 0.06% [5] - The ICE Brent crude oil price increased by 3.48% to $66.29 [5] - The London gold spot price rose by 0.87% to $4,981.31 [5] Group 5 - The Hang Seng Index closed at 26,749.51, up by 0.45% [5] - The Hang Seng China Enterprises Index closed at 9,160.81, up by 0.51% [5] - The Hang Seng Technology Index closed at 5,798.01, up by 0.62% [5]

Core Viewpoint - Dongpeng Beverage (09980) is set to launch an IPO from January 26 to January 29, 2026, aiming to issue 40.89 million shares globally, with a maximum price of HKD 248.00 per share, establishing itself as a leading player in the functional beverage market in China [1][5]. Group 1: Company Overview - Dongpeng Beverage is the number one functional beverage company in China, with the fastest revenue growth among the top 20 listed soft drink companies globally [1]. - The company has maintained its leading position in the Chinese functional beverage market for four consecutive years since 2021, increasing its market share from 15.0% in 2021 to 26.3% in 2024 [1]. - The company has a strong brand presence, recognized for providing high-quality and cost-effective beverage products, solidifying its national influence [1]. Group 2: Sales and Distribution Network - The company has established a comprehensive sales network covering over 4.3 million terminal sales points across nearly 100% of China's prefecture-level cities as of September 30, 2025 [2]. - A dedicated sales team of over 7,500 works closely with distribution partners to enhance product visibility and penetration in the market [2]. - The company employs a refined channel management strategy to improve market penetration and sales efficiency [2]. Group 3: Digitalization and Innovation - Dongpeng Beverage is at the forefront of digitalization in the beverage industry, utilizing a unique "one code for one product" system for precise product traceability [3]. - The company has built an integrated digital operation system that enhances decision-making accuracy and drives sales growth [3]. - As of September 30, 2025, the company has connected with over 280 million consumers and interacted efficiently with over 4.3 million sales points [3]. Group 4: Investment and Fund Utilization - The cornerstone investors have agreed to subscribe for shares worth approximately USD 640 million, contingent upon certain conditions [4]. - The estimated net proceeds from the global offering are approximately HKD 9.994 billion, which will be allocated to various strategic initiatives [5]. - The company plans to use about 36.0% of the net proceeds for capacity expansion and supply chain upgrades, 15.0% for brand building, and 12.0% for exploring overseas market opportunities [5].

Group 1: siRNA Drug Development - The core viewpoint is that siRNA drugs are transitioning from rare diseases to common diseases, driven by technological upgrades and product approvals, marking a new era in targeted therapy [3][4] - siRNA drugs are characterized by strong target expansion capabilities, robust research extensibility, long-lasting effects, and low likelihood of developing resistance, making them a focus for domestic pharmaceutical companies [3][4] - Since 2016, with advancements in the GalNac delivery system and fully modified applications, siRNA drugs have entered a rapid development phase, validating their value in rare diseases and gradually moving towards common disease research [3][4] Group 2: Market Dynamics and Opportunities - The market for small nucleic acid drugs is heating up, with multinational corporations (MNCs) actively engaging in business development (BD) transactions, indicating a sustained interest in this field [4] - Chinese companies are expected to shine in this area due to their engineering advantages, particularly in chemical synthesis, allowing for rapid iteration on leading technologies [4] - The commercialization process of siRNA drugs is focused on common diseases with clear biological mechanisms, where early movers are likely to gain significant commercial benefits [5] Group 3: Industry Trends and Future Outlook - The efficiency and specificity of the GalNac delivery system present opportunities for breakthroughs in liver-targeted therapies and the exploration of previously challenging drug targets [5] - The industry is witnessing a shift towards addressing common diseases, with a focus on new disease areas and advancements in extrahaptic delivery systems [5] - The overall sentiment in the pharmaceutical sector is optimistic, with expectations of significant developments in the siRNA drug space, particularly in large indications such as cardiovascular diseases and chronic hepatitis B [3][4][5]

Investment Rating - The industry investment rating is "Overweight" [3][32]. Core Insights - The report emphasizes the growth logic of the energy drink industry from both macro and micro perspectives, highlighting the importance of channel strategies and operational expenses in driving market share and profitability [5][6]. - The analysis of Monster's historical performance indicates that significant increases in operational expenses often correlate with substantial profit growth in subsequent years, driven by channel transformations [5][9]. - The report suggests that Eastroc Beverage's investment in freezer displays is expected to enhance market share and sales efficiency in the long term, despite short-term cost increases [6][28]. Summary by Sections Review of Monster - Monster experienced four instances of over 50% year-on-year growth in operational expenses since 2000, with subsequent profit growth typically exceeding revenue growth [5][9]. - In 2006, Monster's market share in the U.S. energy drink market reached 23.4%, with a significant increase in sales driven by strategic partnerships and product offerings [10][17]. - By 2008, Monster surpassed Red Bull in market share, achieving a 29.2% share in convenience stores and gas stations, leading to a 93.21% increase in net profit the following year [15][20]. Eastroc Beverage - In the first half of 2025, Eastroc Beverage's sales expenses increased by 37.27% to 1.682 billion yuan, primarily due to a 61.20% rise in channel promotion expenses from freezer investments [28][29]. - The report anticipates that the freezer investments will enhance product visibility and sales efficiency, potentially increasing market share by 20-30% [31][32]. - The long-term outlook for Eastroc is positive, with expectations of improved profitability and market share through strategic channel enhancements [6][28].

Group 1 - Dongpeng Beverage (605499.SH) reported its 2025 semi-annual results, with 203 institutional investors holding a total of 108 million shares, accounting for 20.79% of the total share capital [1] - The top ten institutional investors collectively hold 18.37% of the shares, with an increase of 1.68 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 14 funds increased their holdings, including E Fund Consumer Select Stock and Tianhong CSI Food and Beverage ETF, with a slight increase in the proportion of holdings [2] - 80 public funds reduced their holdings, with a decrease of 0.36% in the proportion of holdings, including Huatai-PB CSI Major Consumer ETF and other funds [2] - 93 new public funds disclosed their holdings this period, including Huatai-PB CSI 300 ETF and E Fund Consumer Industry Mixed Fund [2] - 43 public funds did not disclose their holdings this period, including Jiao Yin Selected Mixed and other funds [2]